Synopsis: The share of this company jumped after reporting strong Q4 FY26 results, driven by exceptional income from a USFDA Priority Review Voucher sale and a sharp profitability turnaround.
The share of this company, which is an Indian clinical-stage biopharmaceutical company focused on drug discovery and the development of novel therapies and delivery systems, gained traction after strong numbers in Q4.
With a market capitalization of Rs 5,538 crore, Sun Pharma Advanced Research Company Ltd’s share made a dy high of Rs 175.50 per share, up by 8.2 percent from its previous day’s close of Rs 162.15 per share. The share of the company delivered a return of 4 percent over the last year.
Results Overview
Fiscal year comparison: revenue from operations surging to Rs 1,879 crore from Rs 72 crore in FY25, marking a growth of over 2,500 percent YoY. Operating margin improved significantly to 85 percent in FY26 from a negative 456 percent in FY25.
The company also turned profitable, reporting a profit after tax of Rs 1,552 crore against a loss of Rs 345 crore in FY25. Additionally, EPS stood at Rs 47.83 in FY26 compared to a negative Rs 10.64 in FY25, reflecting a strong turnaround in earnings performance.
What led the profit and revenue jump in Q4?
During the quarter, the group recognised income of Rs 1,840 crore related to a Priority Review Voucher (PRV) granted by the USFDA on February 3, 2026, for Sezaby®. A PRV is a transferable incentive provided by the regulator that allows faster review timelines for future drug applications. The voucher was subsequently sold by the group on April 30, 2026, for USD 195 million.
The company accounted for the PRV as a non-monetary government grant under Ind AS 20 accounting standards. Accordingly, the fair value of the voucher was recognised in the statement of profit and loss during the quarter, contributing significantly to the company’s earnings performance.
About the Company
Sun Pharma Advanced Research Company Ltd (SPARC) is an Indian clinical-stage biopharmaceutical company focused on drug discovery and the development of novel therapies and delivery systems. Spun off from Sun Pharmaceutical Industries in 2007, it specializes in oncology, neurodegeneration, and immunology
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 21,000% Revenue Growth: Pharma Stock Soars 8% After Reporting Robust Q4 Results appeared first on Trade Brains.